Skip to main content
S&P 5007,807.24-0.06%DOW51,850.55+0.38%NASDAQ27,245.90-0.44%GOLD$4,195.90-0.48%OIL$93.16+1.43%
Delayed
Smart Investors Daily
SID Premium
KM

NASDAQ · KMTS

KESTRA MEDICAL TECHNOLOGIES, LTD.

Healthcare · Medical - Instruments & Supplies

$26.98

Down-$0.07 (-0.26%)

Updated Oct 12, 2026, 8:44 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.28B
P/E ratio
-12.89
Dividend yield
0.00%
52-week range
$17.34 – $30.00
Volume
246.78K
Avg. volume
311.12K

Price performance · KMTS

KMTS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

KMTS closed at $26.98 after 20 trading sessions, up 12.14% for the selected period.

Last close
$26.98
Period change
+12.14%
Period low
$24.06
Period high
$28.46
Daily close
View OHLC price history
KMTS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$25.74$27.13$25.74$26.98246.78K
Oct 8, 2026$26.17$26.175$25.25$25.77379.73K
Oct 7, 2026$26.56$27.61$25.90$26.49399.46K
Oct 6, 2026$28.68$29.2384$27.06$27.10262.26K
Oct 5, 2026$27.64$28.44$27.21$28.34293.64K
Oct 2, 2026$27.52$27.83$26.81$27.43254.76K
Oct 1, 2026$28.14$29.66$26.97$27.115371.35K
Sep 30, 2026$28.46$29.58$28.17$28.29616.81K
Sep 29, 2026$28.48$28.95$27.83$28.46454.96K
Sep 28, 2026$27.04$28.435$26.88$28.13292.9K
Sep 25, 2026$26.02$27.68$25.57$27.14339.7K
Sep 24, 2026$25.45$26.00$25.235$25.76306.09K
Sep 23, 2026$26.03$26.06$25.14$25.51222.73K
Sep 22, 2026$25.16$26.11$24.75$26.09281.57K
Sep 21, 2026$24.69$24.88$24.14$24.77144.13K
Sep 18, 2026$24.35$25.08$24.29$24.431.25M
Sep 17, 2026$24.45$25.01$23.64$24.35287.22K
Sep 16, 2026$25.20$25.3281$23.86$24.08825.01K
Sep 15, 2026$21.90$25.4383$21.56$25.18888.41K
Sep 14, 2026$22.87$24.43$22.795$24.06747.23K

Latest KMTS news

The latest Smart Investors Daily articles mentioning KMTS.

Stock researchCompany · Overview

KMTS research

Overview

Company profile and research snapshot.

Company profile

Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
KMTS recent ratings
DateFirmRatingTarget
Sep 15, 2026BTIGBuy—
Sep 2, 2026BTIGBuy—
Aug 10, 2026JP MorganOverweight—
Jul 21, 2026OppenheimerPerform—
Jul 15, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies

KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek’s list of America’s Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating. “In less than a decade, our team brought the ASSURE® WCD to market and built a rapid

Yahoo · Sep 22, 2026

Kestra Medical Technologies (KMTS) Could Be 17% Undervalued Following Raised Revenue Outlook

Why Kestra Medical Technologies Stock Is Back In Focus Kestra Medical Technologies (KMTS) has drawn fresh attention after first quarter results showed sales of US$30.97 million and a net loss of US$44.09 million, alongside a higher fiscal 2027 revenue outlook. The recent update has landed after a strong run in Kestra Medical Technologies’ share price, with a 90 day share price return of 19.72%. This comes even though the 30 day share price return is down 8.23% and the 1 year total shareholder...

Yahoo · Sep 17, 2026

Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported on September 14 that fiscal first-quarter 2027 revenue increased 60% to $31.0 million. Gross margin reached 56.5%, up from 45.7%, for the quarter ended July 31, 2026. Management raised fiscal 2027 revenue guidance to $141 million from $137 million, implying 48% annual growth. The outlook strengthens the commercial story, […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By